107 results on '"Karagiannis J"'
Search Results
2. The use of wastes as alternative fuels in cement production
- Author
-
Karagiannis, J., primary, Ftikos, Ch., additional, and Nikolopoulos, P., additional
- Published
- 2015
- Full Text
- View/download PDF
3. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe
- Author
-
Vasen, H. F. A., Möslein, G., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Blanco, I., Bulow, S., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I., Rahner, N., Hes, F. J., Hodgson, S., Mecklin, J.-P., Møller, P., Myrhøj, T., Nagengast, F. M., Parc, Y., Ponz de Leon, M., Renkonen-Sinisalo, L., Sampson, J. R., Stormorken, A., Tejpar, S., Thomas, H. J. W., Wijnen, J., Lubinski, J., Järvinen, H., Claes, E., Heinimann, K., Karagiannis, J. A., Lindblom, A., Dove-Edwin, I., and Müller, H.
- Published
- 2010
- Full Text
- View/download PDF
4. PREVALENCE OF CYP2C19 POLYMORPHISMS IN A SUBGROUP OF HELICOBACTER PYLORI POSITIVE (HP+) GREEK PATIENTS: Abstract no.: P13.05
- Author
-
Lycousi, S., Mathou, N., Paraskeva, K. D., Giannakopoulos, A., Artemaki, F., Evgenidou, E., Papasavvas, S., Platsouka, E., and Karagiannis, J. A.
- Published
- 2013
5. The pub1 E3 ubiquitin ligase negatively regulates leucine uptake in response to NH4+ in fission yeast
- Author
-
Karagiannis, J., Saleki, R., and Young, P. G.
- Published
- 1999
- Full Text
- View/download PDF
6. PREVALENCE OF HELICOBACTER PYLORI INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: Abstract no.: P09.16
- Author
-
Mathou, N. G., Paraskeva, K. D., Giannakopoulos, A., Andrikopoulos, E., and Karagiannis, J. A.
- Published
- 2011
7. Sedation in digestive endoscopy: the Athens international position statements
- Author
-
Cohen, L. B., Ladas, S. D., Vargo, J. J., Paspatis, G. A., Bjorkman, D. J., Van der Linden, P., Axon, A. T. R., Axon, A. E., Bamias, G., Despott, E., Dinis-Ribeiro, M., Fassoulaki, A., Hofmann, N., Karagiannis, J. A., Karamanolis, D., Maurer, W., O’Connor, A., Paraskeva, K., Schreiber, F., Triantafyllou, K., Viazis, N., and Vlachogiannakos, J.
- Published
- 2010
- Full Text
- View/download PDF
8. Tolerance of low pH in Schizosaccharomyces pombe requires a functioning pub1 ubiquitin ligase
- Author
-
Saleki, R., Jia, Z., Karagiannis, J., and Young, P. G.
- Published
- 1997
- Full Text
- View/download PDF
9. Cell Cycle Regulatory Proteins Expression (bcl-2, bcl-x, cyclin D1) and Apoptosis in Helicobacter pylori Induced Gastritis
- Author
-
Giannakou, N., Paraskeva, K. D., Ghikonti, I., Kitsanta, P., Tsinga, A., Gaga, G., Theodosiou, D., Karagiannis, J. A., and Spiliadi, C.
- Published
- 2003
10. THE ROLE OF GASTRIC CYTOLOGY IN THE INVESTIGATION OF HELICOBACTER PYLORI
- Author
-
Paraskeva, K., Karakitsos, P., Gianni, L., Spathi, E., Ghiconti, I., and Karagiannis, J. A.
- Published
- 1999
11. HERPES SIMPLEX VIRUS TYPE I (HSV-1) AS A POSSIBLE FACTOR CAUSING PEPTIC ULCER AND ITS RELATIONSHIP WITH HELICOBACTER PYLORI
- Author
-
Tsamakidis, K. I., Panotopoulou, E., Xinopoulos, D., Dimitroulopoulos, D., Christopoulou, M., Fida, A., Karagiannis, J. A., Kottaridis, S., and Paraskevas, E.
- Published
- 1999
12. Combined antioncogene and cytotoxic treatment against human pancreatic cancer cells 01.06
- Author
-
Giannios, J. N., Dervenis, Ch., and Karagiannis, J. A.
- Published
- 1997
13. When perforation is not the culprit : case report and systematic review of mechanical small-bowel obstruction complicating colonoscopy.
- Author
-
Papastergiou, V., Mathou, N., Manes, K., Maniatis, P., Paraskeva, K., Evgenidi, A., Giannakopoulos, A., and Karagiannis, J. A.
- Published
- 2018
14. Expression of Bax protein in gastric carcinomas. A clinicopathological and immunohistochemical study
- Author
-
Anagnostopoulos, G. K., Stefanou, D., Arkoumani, E., Chalkley, L., Karagiannis, J., Paraskeva, K., Mathou, N., Dellaporta, E., Tsianos, E., and Agnantis, N. J.
- Subjects
Aged, 80 and over ,Coloring Agents/diagnostic use ,Male ,bcl-2-Associated X Protein/*analysis ,Antibodies, Monoclonal/diagnostic use ,Stomach Neoplasms/*pathology ,Cell Differentiation/genetics ,Gastric Mucosa/pathology ,Middle Aged ,Prognosis ,Immunohistochemistry ,Survival Rate ,Gene Expression Regulation, Neoplastic/genetics ,Lymphatic Metastasis/pathology ,Disease Progression ,Lymph Nodes/pathology ,Humans ,Female ,Carcinoma/pathology/secondary ,Adenocarcinoma/*pathology/secondary ,Aged ,Neoplasm Staging - Abstract
BACKGROUND AND STUDY AIMS: Reduced Bax protein expression has been shown to be a negative prognostic factor in patients with breast, ovarian, colorectal, esophageal and pancreatic cancer. Our aim was to immunohistochemically study Bax protein expression in gastric carcinomas and correlate its expression with clinicopathological parameters and prognosis. PATIENTS AND METHODS: Immunohistochemistry was performed, using a monoclonal antibody against bax, in paraffin-embedded tumor specimens from 47 cases of gastric cancer. RESULTS: Positive staining for the Bax protein was found in 20/47 (42.4%) adenocarcinomas examined. Negative Bax protein expression in tumour cells was correlated with lymph node metastasis (P < 0.05), and degree of differentiation (p < 0.05). Univariate analysis showed that the variables with a significant negative impact on survival were: high TNM tumour stage, depth of penetration in the gastric wall, lymph node involvement, and Bax protein expression. Multivariate analysis showed that the only variable with an impact on survival was Bax protein expression (p < 0.05, Relative Risk: 3.34). Kaplan-Meier curves showed that the 5-year survival was 36.8% in cases with positive compared with 16% in cases with negative Bax protein expression (p = 0.0427). CONCLUSION: Negative Bax expression in gastric cancer is associated with de-differentiation, lymph node metastases, and poor clinical prognosis. Bax protein expression might play an important role in the development and phenotypic differentiation of gastric carcinomas and tumor progression. Acta Gastroenterol Belg
- Published
- 2007
15. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts.
- Author
-
Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I. M., Genuardi, Maurizio, Hes, F. J., Hodgson, S. V., Karagiannis, J. A., Lalloo, F., Lindblom, A., Mecklin, J. -P., Moller, P., Myrhoj, T., Nagengast, F. M., Parc, Y., De Leon, M. P., Renkonen-Sinisalo, L., Sampson, J. R., Stormorken, A., Sijmons, R. H., Tejpar, S., Thomas, H. J. W., Rahner, N., Wijnen, J. T., Jarvinen, H. J., Moslein, G., Maurizio Genuardi. (ORCID:0000-0002-7410-8351), Vasen, H. F. A., Blanco, I., Aktan-Collan, K., Gopie, J. P., Alonso, A., Aretz, S., Bernstein, I., Bertario, L., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I. M., Genuardi, Maurizio, Hes, F. J., Hodgson, S. V., Karagiannis, J. A., Lalloo, F., Lindblom, A., Mecklin, J. -P., Moller, P., Myrhoj, T., Nagengast, F. M., Parc, Y., De Leon, M. P., Renkonen-Sinisalo, L., Sampson, J. R., Stormorken, A., Sijmons, R. H., Tejpar, S., Thomas, H. J. W., Rahner, N., Wijnen, J. T., Jarvinen, H. J., Moslein, G., and Maurizio Genuardi. (ORCID:0000-0002-7410-8351)
- Abstract
Lynch syndrome (LS) is characterised by the development of colorectal cancer, endometrial cancer and various other cancers, and is caused by a mutation in one of the mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. In 2007, a group of European experts (the Mallorca group) published guidelines for the clinical management of LS. Since then substantial new information has become available necessitating an update of the guidelines. In 2011 and 2012 workshops were organised in Palma de Mallorca. A total of 35 specialists from 13 countries participated in the meetings. The first step was to formulate important clinical questions. Then a systematic literature search was performed using the Pubmed database and manual searches of relevant articles. During the workshops the outcome of the literature search was discussed in detail. The guidelines described in this paper may be helpful for the appropriate management of families with LS. Prospective controlled studies should be undertaken to improve further the care of these families
- Published
- 2013
16. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe
- Author
-
Vasen, H F A, Möslein, G, Alonso, A, Aretz, S, Bernstein, I, Bertario, L, Blanco, I, Bulow, S, Burn, J, Capella, G, Colas, C, Engel, C, Frayling, I, Rahner, N, Hes, F J, Hodgson, S, Mecklin, J-P, Møller, P, Myrhøj, T, Nagengast, F M, Parc, Y, Ponz de Leon, M, Renkonen-Sinisalo, L, Sampson, J R, Stormorken, A, Tejpar, S, Thomas, H J W, Wijnen, J, Lubinski, J, Järvinen, H, Claes, E, Heinimann, K, Karagiannis, J A, Lindblom, A, Dove-Edwin, I, Müller, H, Vasen, H F A, Möslein, G, Alonso, A, Aretz, S, Bernstein, I, Bertario, L, Blanco, I, Bulow, S, Burn, J, Capella, G, Colas, C, Engel, C, Frayling, I, Rahner, N, Hes, F J, Hodgson, S, Mecklin, J-P, Møller, P, Myrhøj, T, Nagengast, F M, Parc, Y, Ponz de Leon, M, Renkonen-Sinisalo, L, Sampson, J R, Stormorken, A, Tejpar, S, Thomas, H J W, Wijnen, J, Lubinski, J, Järvinen, H, Claes, E, Heinimann, K, Karagiannis, J A, Lindblom, A, Dove-Edwin, I, and Müller, H
- Abstract
Udgivelsesdato: 2010-Jun, Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is associated with a highly penetrant dominant inherited syndrome. The most common inherited form of non-polyposis CRC is the Lynch syndrome which is responsible for about 2-4% of all cases. Surveillance of individuals at high risk for CRC prevents the development of advanced CRC. About 1 million individuals in Western Europe are at risk for Lynch syndrome. We performed a survey to evaluate the strategies currently used to identify individuals at high risk for CRC in 14 Western European countries. Questionnaires were distributed amongst members of a European collaborative group of experts that aims to improve the prognosis of families with hereditary CRC. The survey showed that in all countries obtaining a family history followed by referral to clinical genetics centres of suspected cases was the main strategy to identify familial and hereditary CRC. In five out of seven countries with a (regional or national) CRC population screening program, attention was paid in the program to the detection of familial CRC. In only one country were special campaigns organized to increase the awareness of familial CRC among the general population. In almost all countries, the family history is assessed when a patient visits a general practitioner or hospital. However, the quality of family history taking was felt to be rather poor. Microsatellite instability testing (MSI) or immunohistochemical analysis (IHC) of CRC are usually recommended as tools to select high-risk patients for genetic testing and are performed in most countries in patients suspected of Lynch syndrome. In one country, IHC was recommended in all new cases of CRC. In most countries there are no specific programs on cancer genetics in the teaching curriculum for medical doctors. In conclusion, the outcome of this survey and the discussions within an European expert group may be used to improve the strategies to identify
- Published
- 2010
17. Ethical issues in endoscopy: patient satisfaction, safety in elderly patients, palliation, and relations with industry. Second European Symposium on Ethics in Gastroenterology and Digestive Endoscopy, Kos, Greece, July 2006.
- Author
-
Ladas, S, Novis, B, Triantafyllou, Konstantinos, Schoefl, R, Rokkas, T, Stanciu, C, Isaacs, P, Willich, S N, Ronn, O, Dremel, H, Livadas, G, Egan, B J, Boyacioglu, S, Selimovic, A, Pulanic, R, Karagiannis, J A, Van Vooren, Jean-Paul, Kouroumalis, E, O'Morain, Colm, Nowak, A, Devière, Jacques, Malfertheiner, P, Axon, Anthony, Ladas, S, Novis, B, Triantafyllou, Konstantinos, Schoefl, R, Rokkas, T, Stanciu, C, Isaacs, P, Willich, S N, Ronn, O, Dremel, H, Livadas, G, Egan, B J, Boyacioglu, S, Selimovic, A, Pulanic, R, Karagiannis, J A, Van Vooren, Jean-Paul, Kouroumalis, E, O'Morain, Colm, Nowak, A, Devière, Jacques, Malfertheiner, P, and Axon, Anthony
- Abstract
Consensus Development Conference, Journal Article, info:eu-repo/semantics/published
- Published
- 2007
18. P106 Health related quality of life and work productivity in Greek patients with inflammatory bowel disease
- Author
-
Viazis, N., primary, Mantzaris, G., additional, Karagiannis, J., additional, and Karamanolis, D., additional
- Published
- 2012
- Full Text
- View/download PDF
19. Patient and endoscopist radiation doses during ERCP procedures
- Author
-
Tsapaki, V., primary, Paraskeva, K. D., additional, Mathou, N., additional, Andrikopoulos, E., additional, Tentas, P., additional, Triantopoulou, C., additional, and Karagiannis, J. A., additional
- Published
- 2011
- Full Text
- View/download PDF
20. Recommendations to improve identification of hereditary and familial colorectal cancer in Europe
- Author
-
Vasen, H. F. A., primary, Möslein, G., additional, Alonso, A., additional, Aretz, S., additional, Bernstein, I., additional, Bertario, L., additional, Blanco, I., additional, Bulow, S., additional, Burn, J., additional, Capella, G., additional, Colas, C., additional, Engel, C., additional, Frayling, I., additional, Rahner, N., additional, Hes, F. J., additional, Hodgson, S., additional, Mecklin, J.-P., additional, Møller, P., additional, Myrhøj, T., additional, Nagengast, F. M., additional, Parc, Y., additional, Ponz de Leon, M., additional, Renkonen-Sinisalo, L., additional, Sampson, J. R., additional, Stormorken, A., additional, Tejpar, S., additional, Thomas, H. J. W., additional, Wijnen, J., additional, Lubinski, J., additional, Järvinen, H., additional, Claes, E., additional, Heinimann, K., additional, Karagiannis, J. A., additional, Lindblom, A., additional, Dove-Edwin, I., additional, and Müller, H., additional
- Published
- 2009
- Full Text
- View/download PDF
21. The use of wastes as alternative fuels in cement production
- Author
-
Karagiannis, J., primary, Ftikos, Ch., additional, and Nikolopoulos, P., additional
- Published
- 2008
- Full Text
- View/download PDF
22. Ethical issues in endoscopy: patient satisfaction, safety in elderly patients, palliation, and relations with industry
- Author
-
Ladas, S., primary, Novis, B., additional, Triantafyllou, K., additional, Schoefl, R., additional, Rokkas, T., additional, Stanciu, C., additional, Isaacs, P., additional, Willich, S., additional, Ronn, O., additional, Dremel, H., additional, Livadas, G., additional, Egan, B., additional, Boyacioglu, S., additional, Selimovic, A., additional, Pulanic, R., additional, Karagiannis, J., additional, Van Vooren, J., additional, Kouroumalis, E., additional, O’Morain, C., additional, Nowak, A., additional, Deviere, J., additional, Malfertheiner, P., additional, and Axon, A., additional
- Published
- 2007
- Full Text
- View/download PDF
23. Impaired Nitric Oxide Function in the Basilar Artery of the Obese Zucker Rat
- Author
-
Karagiannis, J., primary, Reid, J. J., additional, Darby, I., additional, Roche, P., additional, Rand, M. J., additional, and Li, C. G., additional
- Published
- 2003
- Full Text
- View/download PDF
24. Radiation doses to patients from endoscopic retrograde cholangiopancreatography examinations and image quality considerations
- Author
-
A. Tsalafoutas, I., primary, D. Paraskeva, K., additional, N. Yakoumakis, E., additional, E. Vassilaki, A., additional, N. Maniatis, P., additional, A. Karagiannis, J., additional, and D. Koulentianos, E., additional
- Published
- 2003
- Full Text
- View/download PDF
25. The involvement of cannabinoid receptors and intracellular gap junctions in NO/PGI2-independent relaxations in rat isolated renal artery
- Author
-
Karagiannis, J, primary
- Published
- 2000
- Full Text
- View/download PDF
26. The pub1 E3 ubiquitin ligase negatively regulates leucine uptake in response to NH 4 + in fission yeast
- Author
-
Karagiannis, J., primary, Saleki, R., additional, and Young, P. G., additional
- Published
- 1999
- Full Text
- View/download PDF
27. Progress in Cell Cycle Research.Laurent Meijer , Silvanna Guidet , Lee Vogel
- Author
-
Karagiannis, J., primary and Young, Paul G., additional
- Published
- 1998
- Full Text
- View/download PDF
28. Cellular hypersensitivity to a synthetic dodecapeptide derived from human adenovirus 12 which resembles a sequence of A-gliadin in patients with coeliac disease.
- Author
-
Mantzaris, G J, primary, Karagiannis, J A, additional, Priddle, J D, additional, and Jewell, D P, additional
- Published
- 1990
- Full Text
- View/download PDF
29. 2nd Meeting of Mediterranean Societies of Pancreatology.
- Author
-
Dervenis, C., Chatzitheoklitos, E., Skaltsas, S., and Karagiannis, J.
- Published
- 2001
- Full Text
- View/download PDF
30. Progress in Cell Cycle Research. Laurent Meijer Silvanna Guidet Lee Vogel
- Author
-
Karagiannis, J. and Young, Paul G.
- Published
- 1998
31. Very-Long Instruction Word Digital Signal Processor based on the Logarithmic Number System
- Author
-
Vassilis Paliouras, Karagiannis, J., Aggouras, G., and Stouraitis, T.
32. A very-long instruction word digital signal processor based on the logarithmic number system
- Author
-
Paliouras, V., primary, Karagiannis, J., additional, Aggouras, C., additional, and Stouraitis, T., additional
- Full Text
- View/download PDF
33. Decoding the informational properties of the RNA polymerase II Carboxy Terminal Domain
- Author
-
Karagiannis Jim
- Subjects
Transcription ,RNA polymerase II ,Carboxy terminal domain ,Information theory ,Phosphorylation ,Kinase ,Phosphatase ,Fission yeast ,Budding yeast ,Medicine ,Biology (General) ,QH301-705.5 ,Science (General) ,Q1-390 - Abstract
Abstract Background The largest sub-unit of RNA polymerase II, Rpb1p, has long been known to be subject to post-translational modifications that influence various aspects of pre-mRNA processing. However, the portion of the Rpb1p molecule subject to these modifications – the carboxy-terminal domain or CTD – remains the subject of much fascination. Intriguingly, the CTD possesses a unique repetitive structure consisting of multiple repeats of the heptapeptide sequence, Y1S2P3T4S5P6S7. While these repeats are critical for viability, they are not required for basal transcriptional activity in vitro. This suggests that – even though the CTD is not catalytically essential – it must perform other critical functions in eukaryotes. Presentation of the Hypothesis By formally applying the long-standing mathematical principles of information theory, I explore the hypothesis that complex post-translational modifications of the CTD represent a means for the dynamic “programming” of Rpb1p and thus for the discrete modulation of the expression of specific gene subsets in eukaryotes. Testing the Hypothesis Empirical means for testing the informational capacity and regulatory potential of the CTD – based on simple genetic analysis in yeast model systems – are put forward and discussed. Implications of the Hypothesis These ideas imply that the controlled manipulation of CTD effectors could be used to “program” the CTD and thus to manipulate biological processes in eukaryotes in a definable manner.
- Published
- 2012
- Full Text
- View/download PDF
34. A conserved histone deacetylase with a role in the regulation of cytokinesis in Schizosaccharomyces pombe
- Author
-
Grewal Charnpal, Hickmott Jack, Rentas Stefan, and Karagiannis Jim
- Subjects
Fission yeast ,Cytokinesis ,Cell division ,Histone deacetylase ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Background In Schizosaccharomyces pombe the SET domain protein, Set3p - together with its interacting partners, Snt1p, and Hif2p - form a complex that aids in preventing cell division failure upon mild cytokinetic stress. Intriguingly, the human orthologs of these proteins (MLL5, NCOR2, and TBL1X) are also important for the faithful completion of cytokinesis in tissue culture cells. Since MLL5, NCOR2, and TBL1X form a complex with the histone deacetylase, HDAC3, we sought to determine if an orthologous counterpart played a regulatory role in fission yeast cytokinesis. Results In this report we identify the hos2 gene as the fission yeast HDAC3 ortholog. We show that Hos2p physically interacts with Set3p, Snt1p, and Hif2p, and that hos2∆ mutants are indeed compromised in their ability to reliably complete cell division in the presence of mild cytokinetic stresses. Furthermore, we demonstrate that over-expression of hos2 causes severe morphological and cytokinetic defects. Lastly, through recombinase mediated cassette exchange, we show that expression of human HDAC3 complements the cytokinetic defects exhibited by hos2∆ cells. Conclusions These data support a model in which Hos2p functions as an essential component of the Set3p-Snt1p-Hif2p complex with respect to the regulation of cytokinesis. The ability of human HDAC3 to complement the cytokinesis defects associated with the deletion of the hos2 gene suggests that further analysis of this system could provide insight into the role of HDAC3 in both the regulation of cell division, as well as other biological processes influenced by HDAC3 deacetylation.
- Published
- 2012
- Full Text
- View/download PDF
35. A very-long instruction word digital signal processor based on the logarithmic number system.
- Author
-
Paliouras, V., Karagiannis, J., Aggouras, C., and Stouraitis, T.
- Published
- 1998
- Full Text
- View/download PDF
36. F008: The involvement of cannabinoid receptors and intracellular gap junctions in NO/PGI2-independent relaxations in rat isolated renal artery.
- Author
-
Karagiannis, J. and Li, C.G.
- Published
- 2000
- Full Text
- View/download PDF
37. Identification of risk components in exercise for the low back.
- Author
-
Tornatora, B., Karagiannis, J., Polus, B.I., and Walsh, M.J.
- Subjects
- *
CHIROPRACTIC - Published
- 1994
38. F008: The involvement of cannabinoid receptors and intracellular gap junctions in NO/PGI2-independent relaxations in rat isolated renal artery
- Author
-
Karagiannis, J. and Li, C.G.
- Abstract
Endothelium derived hyperpolarizing factor (EDHF) is an important mediator of nitric oxide (NO)/prostacyclin (PGI
2 ) independent vasodilatation in various vascular beds (Feletou & Vanhoutte, 1988). The chemical identity of EDHF and its mechanism of action has not been fully elucidated, but it may differ between vascular regions and species. Studies suggest that intra-epithelial cell gap junctions and cannabinoid receptors may be involved in EDHF-mediated responses (Triggle et al, 1999). In this study, we examined the effects of the cannabinoid receptor antagonist SR141716A and the specific gap junction inhibitor GAP 27 peptide on EDHF-mediated responses induced by the muscarinic agonist carbachol in the rat renal artery. Segments of the renal artery were set up in a myograph as previously described (Jiang et al, 1998). The preparations were treated with the nitric oxide synthase inhibitor NG-nitro-L -arginine methyl ester (L -NAME; 100 µM) and the cyclooxygenase inhibitor indomethacin (10 µM) to eliminate contributions by NO and PGI2 , respectively. Carbachol-induced relaxations were significantly reduced by the large conductance Ca2+-activated K+ channel inhibitor charybdotoxin (200 nM) and Na+/K+ATPase inhibitor ouabain (30 µM), which is in accord with previous observations on the activity of EDHF in this tissue (Jiang et al, 1998). The cannabinoid receptor antagonist SR141716A (30 µM) and the gap junction inhibitor GAP 27 peptide (300 µM) significantly reduced carbachol but not the NO donor sodium nitroprusside (SNP) induced relaxations. However, the combination of SR141716A and GAP 27 peptide did not produce a further inhibition of carbachol relaxations that did either drug alone. These findings indicate a possible involvement of cannabinoid receptors and gap junctions in EDHF-mediated vasodilatation induced by carbachol in the rat renal artery. Feletou M & Vanhoutte PM (1988) Br J Pharmacol, 93, 515–524. Triggle CR et al. (1999) Clin Exp Pharmacol Physiol, 26, 176–179. Jiang F et al. (1998) Proc Aust Soc Clin Exp Pharmacol Toxicol, 5, 46.- Published
- 2000
- Full Text
- View/download PDF
39. New biological books: Cellular biology.
- Author
-
Karagiannis, J. and Young, Paul G.
- Subjects
- PROGRESS in Cell Cycle Research (Book)
- Abstract
Reviews the book `Progress in Cell Cycle Research. Volume 2,' edited by Laurent Meijer, Silvanna Guidet and Lee Vogel.
- Published
- 1998
40. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial
- Author
-
Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward V Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J Sandborn, Humberto Aguilar, Tariq Ahmad, Evangelos Akriviadis, Xavier Aldeguer Mante, Istvan Altorjay, Ashwin Ananthakrishnan, Vibeke Andersen, Montserrat Andreu Garcia, Guy Aumais, Irit Avni-Biron, Jeffrey Axler, Kamran Ayub, Filip Baert, Mauro Bafutto, George Bamias, Isaac Bassan, Curtis Baum, Laurent Beaugerie, Brian Behm, Pradeep Bekal, Michael Bennett, Fernando Bermejo San Jose, Charles Bernstein, Dominik Bettenworth, Sudhir Bhaskar, Livia Biancone, Bahri Bilir, Michael Blaeker, Stuart Bloom, Verle Bohman, Francisco Javier Bosques Padilla, Yoram Bouhnik, Gerd Bouma, Raymond Bourdages, Stephan Brand, Brian Bressler, Markus Brückner, Carsten Buening, Franck Carbonnel, Thomas Caves, Jonathon Chapman, Jae Hee Cheon, Naoki Chiba, Camelia Chioncel, Dimitrios Christodoulou, Martin Clodi, Albert Cohen, Gino Roberto Corazza, Richard Corlin, Rocco Cosintino, Fraser Cummings, Robin Dalal, Silvio Danese, Marc De Maeyer, Carlos Fernando De Magalhães Francesconi, Aminda De Silva, Henry Debinski, Pierre Desreumaux, Olivier Dewit, Geert D'Haens, Sandra Di Felice Boratto, John Nik Ding, Tyler Dixon, Gerald Dryden, George Aaron Du Vall, Matthias Ebert, Ana Echarri Piudo, Robert Ehehalt, Magdy Elkhashab, Craig Ennis, Jason Etzel, Jan Fallingborg, Brian Feagan, Roland Fejes, Daniel Ferraz de Campos Mazo, Valéria Ferreira de Almeida Borges, Andreas Fischer, Alan Fixelle, Mark Fleisher, Sharyle Fowler, Bradley Freilich, Keith Friedenberg, Walter Fries, Csaba Fulop, Mathurin Fumery, Sergio Fuster, Gyula G Kiss, Santiago Garcia Lopez, Sonja Gassner, Kanwar Gill, Cyrielle Gilletta de Saint Joseph, Philip Ginsburg, Paolo Gionchetti, Eran Goldin, Adrian-Eugen Goldis, Hector Alejandro Gomez Jaramillo, Maciej Gonciarz, Glenn Gordon, Daniel Green, Jean-Charles Grimaud, Rogelio Guajardo Rodriguez, Zoltan Gurzo, Alexandra Gutierrez, Tibor Gyökeres, Ki Baik Hahm, Stephen Hanauer, John Hanson, William Harlan III, Peter Hasselblatt, Buhussain Hayee, Xavier Hebuterne, Peter Hendy, Melvin Heyman, Peter Higgins, Raouf Hilal, Pieter Hindryckx, Frank Hoentjen, Peter Hoffmann, Frank Holtkamp-Endemann, Gerald Holtmann, Gyula Horvat, Stefanie Howaldt, Samuel Huber, Ikechukwu Ibegbu, Maria Isabel Iborra Colomino, Peter Irving, Kim Isaacs, Kiran Jagarlamudi, Rajesh Jain, Sender Jankiel Miszputen, Jeroen Jansen, Jennifer Jones, John Karagiannis, Nicholas Karyotakis, Arthur Kaser, Lior Katz, Seymour Katz, Leo Katz, Nirmal Kaur, Edita Kazenaite, Reena Khanna, Sunil Khurana, Joo Sung Kim, Young-Ho Kim, Sung Kook Kim, Dongwoo Kim, Jochen Klaus, Dariusz Kleczkowski, Pavel Kohout, Bartosz Korczowski, Georgios Kouklakis, Ioannis Koutroubakis, Richard Krause, Tunde Kristof, Ian Kronborg, Annette Krummenerl, Limas Kupcinskas, Jorge Laborda Molteni, David Laharie, Adi Lahat-zok, Jonghun Lee, Kang-Moon Lee, Rupert Leong, Henry Levine, Jimmy Limdi, James Lindsay, Nilesh Lodhia, Edward Loftus, Randy Longman, Pilar Lopez Serrano, Edouard Louis, Maria Helena Louzada Pereira, John Lowe, Stefan Lueth, Milan Lukas, Giovanni Maconi, Finlay Macrae, Laszlo Madi-Szabo, Uma Mahadevan-Velayos, Everson Fernando Malluta, Fazia Mana, Peter Mannon, Gerasimos Mantzaris, Ignacio Marin Jimenez, Maria Dolores Martin Arranz, Radu-Bogdan Mateescu, Felipe Mazzoleni, Agnieszka Meder, Ehud Melzer, Jessica Mertens, Konstantinos Mimidis, Brent Mitchell, Tamas Molnar, Gregory Moore, Luis Alonso Morales Garza, Reme Mountifield, Vinciane Muls, Charles Murray, Bela Nagy, Markus Neurath, Augustin Nguyen, Remo Panaccione, William Pandak, Julian Panes Diaz, Jihye Park, Luca Pastorelli, Bhaktasharan Patel, Markus Peck-Radosavljevic, Gyula Pecsi, Farhad Peerani, Javier Perez Gisbert, Martin Pesta, Robert Petryka, Raymond Phillips, Marieke Pierik, Vijayalakshmi Pratha, Vlastimil Prochazka, Istvan Racz, Graham Radford-Smith, Daniel Ramos Castañeda, Odery Ramos Júnior, Jaroslaw Regula, Jean-Marie Reimund, Bryan Robbins, Xavier Roblin, Francesca Rogai, Gerhard Rogler, Jerzy Rozciecha, David Rubin, Azalia Yuriria Ruiz Flores, Maciej Rupinski, Grazyna Rydzewska, Sumona Saha, Simone Saibeni, Agnes Salamon, Zoltan Sallo, Bruce Salzberg, Douglas Samuel, Sunil Samuel, William Sandborn, Edoardo Vincenzo Savarino, Anja Schirbel, Robert Schnabel, Stefan Schreiber, John Scott, Shahriar Sedghi, Frank Seibold, Jakob Seidelin, Ursula Seidler, Ahmad Shaban, Ira Shafran, Aasim Sheikh, Alex Sherman, Haim Shirin, Patryk Smolinski, Geun Am Song, Konstantinos Soufleris, Alexander Speight, Dirk Staessen, Andreas Stallmach, Michael Staun, Daniel Stein, Hillary Steinhart, Jonathas Stifft, David Stokesberry, Andreas Sturm, Keith Sultan, Gyorgy Szekely, Kuldeep Tagore, Hugo Tanno, Lena Thin, Syed Thiwan, Carlton Thomas, Michal Tichy, Gabor Tamas Toth, Zsolt Tulassay, Jan Ulbrych, John Valentine, Marta Varga, Eduardo Vasconcellos, Byron Vaughn, Brenda Velasco, Francisco Velazquez, Severine Vermeire, Erica Villa, Aron Vincze, Harald Vogelsang, Miroslava Volfova, Lucine Vuitton, Petr Vyhnalek, Peter Wahab, Jens Walldorf, Mattitiahu Waterman, John Weber, L. Michael Weiss, Anna Wiechowska-Kozlowska, Elise Wiesner, Thomas Witthoeft, Robert Wohlman, Barbara Wozniak-Stolarska, Bruce Yacyshyn, Byong-Duk Ye, Ziad Younes, Lígia Yukie Sassaki, Cyrla Zaltman, Stefan Zeuzem, Neurosurgery, ANS - Neurovascular Disorders, Gastroenterology and Hepatology, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Peyrin-Biroulet L., Hart A., Bossuyt P., Long M., Allez M., Juillerat P., Armuzzi A., Loftus E.V., Ostad-Saffari E., Scalori A., Oh Y.S., Tole S., Chai A., Pulley J., Lacey S., Sandborn W.J., Aguilar H., Ahmad T., Akriviadis E., Aldeguer Mante X., Altorjay I., Ananthakrishnan A., Andersen V., Andreu Garcia M., Aumais G., Avni-Biron I., Axler J., Ayub K., Baert F., Bafutto M., Bamias G., Bassan I., Baum C., Beaugerie L., Behm B., Bekal P., Bennett M., Bermejo San Jose F., Bernstein C., Bettenworth D., Bhaskar S., Biancone L., Bilir B., Blaeker M., Bloom S., Bohman V., Bosques Padilla F.J., Bouhnik Y., Bouma G., Bourdages R., Brand S., Bressler B., Bruckner M., Buening C., Carbonnel F., Caves T., Chapman J., Cheon J.H., Chiba N., Chioncel C., Christodoulou D., Clodi M., Cohen A., Corazza G.R., Corlin R., Cosintino R., Cummings F., Dalal R., Danese S., De Maeyer M., De Magalhaes Francesconi C.F., De Silva A., Debinski H., Desreumaux P., Dewit O., D'Haens G., Di Felice Boratto S., Ding J.N., Dixon T., Dryden G., Du Vall G.A., Ebert M., Echarri Piudo A., Ehehalt R., Elkhashab M., Ennis C., Etzel J., Fallingborg J., Feagan B., Fejes R., Ferraz de Campos Mazo D., Ferreira de Almeida Borges V., Fischer A., Fixelle A., Fleisher M., Fowler S., Freilich B., Friedenberg K., Fries W., Fulop C., Fumery M., Fuster S., G Kiss G., Garcia Lopez S., Gassner S., Gill K., Gilletta de Saint Joseph C., Ginsburg P., Gionchetti P., Goldin E., Goldis A.-E., Gomez Jaramillo H.A., Gonciarz M., Gordon G., Green D., Grimaud J.-C., Guajardo Rodriguez R., Gurzo Z., Gutierrez A., Gyokeres T., Hahm K.B., Hanauer S., Hanson J., Harlan III W., Hasselblatt P., Hayee B., Hebuterne X., Hendy P., Heyman M., Higgins P., Hilal R., Hindryckx P., Hoentjen F., Hoffmann P., Holtkamp-Endemann F., Holtmann G., Horvat G., Howaldt S., Huber S., Ibegbu I., Iborra Colomino M.I., Irving P., Isaacs K., Jagarlamudi K., Jain R., Jankiel Miszputen S., Jansen J., Jones J., Karagiannis J., Karyotakis N., Kaser A., Katz L., Katz S., Kaur N., Kazenaite E., Khanna R., Khurana S., Kim J.S., Kim Y.-H., Kim S.K., Kim D., Klaus J., Kleczkowski D., Kohout P., Korczowski B., Kouklakis G., Koutroubakis I., Krause R., Kristof T., Kronborg I., Krummenerl A., Kupcinskas L., Laborda Molteni J., Laharie D., Lahat-zok A., Lee J., Lee K.-M., Leong R., Levine H., Limdi J., Lindsay J., Lodhia N., Loftus E., Longman R., Lopez Serrano P., Louis E., Louzada Pereira M.H., Lowe J., Lueth S., Lukas M., Maconi G., Macrae F., Madi-Szabo L., Mahadevan-Velayos U., Malluta E.F., Mana F., Mannon P., Mantzaris G., Marin Jimenez I., Martin Arranz M.D., Mateescu R.-B., Mazzoleni F., Meder A., Melzer E., Mertens J., Mimidis K., Mitchell B., Molnar T., Moore G., Morales Garza L.A., Mountifield R., Muls V., Murray C., Nagy B., Neurath M., Nguyen A., Panaccione R., Pandak W., Panes Diaz J., Park J., Pastorelli L., Patel B., Peck-Radosavljevic M., Pecsi G., Peerani F., Perez Gisbert J., Pesta M., Petryka R., Phillips R., Pierik M., Pratha V., Prochazka V., Racz I., Radford-Smith G., Ramos Castaneda D., Ramos Junior O., Regula J., Reimund J.-M., Robbins B., Roblin X., Rogai F., Rogler G., Rozciecha J., Rubin D., Ruiz Flores A.Y., Rupinski M., Rydzewska G., Saha S., Saibeni S., Salamon A., Sallo Z., Salzberg B., Samuel D., Samuel S., Sandborn W., Savarino E.V., Schirbel A., Schnabel R., Schreiber S., Scott J., Sedghi S., Seibold F., Seidelin J., Seidler U., Shaban A., Shafran I., Sheikh A., Sherman A., Shirin H., Smolinski P., Song G.A., Soufleris K., Speight A., Staessen D., Stallmach A., Staun M., Stein D., Steinhart H., Stifft J., Stokesberry D., Sturm A., Sultan K., Szekely G., Tagore K., Tanno H., Thin L., Thiwan S., Thomas C., Tichy M., Toth G.T., Tulassay Z., Ulbrych J., Valentine J., Varga M., Vasconcellos E., Vaughn B., Velasco B., Velazquez F., Vermeire S., Villa E., Vincze A., Vogelsang H., Volfova M., Vuitton L., Vyhnalek P., Wahab P., Walldorf J., Waterman M., Weber J., Weiss L.M., Wiechowska-Kozlowska A., Wiesner E., Witthoeft T., Wohlman R., Wozniak-Stolarska B., Yacyshyn B., Ye B.-D., Younes Z., Yukie Sassaki L., Zaltman C., and Zeuzem S.
- Subjects
Adult ,Male ,Ulcerative Colitis Flare ,medicine.medical_specialty ,Asia ,Adolescent ,Oceania ,Population ,Antibodies, Monoclonal, Humanized ,Injections, Subcutaneou ,Placebo ,Severity of Illness Index ,law.invention ,Middle East ,Young Adult ,Maintenance therapy ,Randomized controlled trial ,law ,Internal medicine ,Gastrointestinal Agent ,medicine ,Adverse effect ,education ,Aged ,Aged, 80 and over ,Tumor Necrosis Factor Inhibitor ,education.field_of_study ,Hepatology ,business.industry ,Remission Induction ,Gastroenterology ,Middle Aged ,South America ,medicine.disease ,Ulcerative colitis ,Europe ,Treatment Outcome ,Etrolizumab ,North America ,Colitis, Ulcerative ,Female ,business ,Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5] ,Human - Abstract
Summary Background Etrolizumab is a gut-targeted, anti-β7 integrin, monoclonal antibody. In an earlier phase 2 induction study, etrolizumab significantly improved clinical remission compared with placebo in patients with moderately to severely active ulcerative colitis. We aimed to evaluate the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-tumour necrosis factor (TNF) agents. Methods HICKORY was a multicentre, phase 3, double-blind, placebo-controlled study in adult (18–80 years) patients with moderately to severely active ulcerative colitis (Mayo Clinic total score [MCS] of 6–12 with an endoscopic subscore of ≥2, a rectal bleeding subscore of ≥1, and a stool frequency subscore of ≥1) previously treated with TNF inhibitors. Patients were recruited from 184 treatment centres across 24 countries in North America, South America, Europe, Asia, Oceania, and the Middle East. Patients needed to have an established diagnosis of ulcerative colitis for at least 3 months, corroborated by both clinical and endoscopic evidence, and evidence of disease extending at least 20 cm from the anal verge. In cohort 1, patients received open-label etrolizumab 105 mg every 4 weeks for a 14-week induction period. In cohort 2, patients were randomly assigned (4:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks for the 14-week induction phase. Patients in either cohort achieving clinical response to etrolizumab induction were eligible for the maintenance phase, in which they were randomly assigned (1:1) to receive subcutaneous etrolizumab 105 mg or placebo every 4 weeks through to week 66. Randomisation was stratified by baseline concomitant treatment with corticosteroids, concomitant treatment with immunosuppressants (induction randomisation only), baseline disease activity, week 14 MCS remission status (maintenance randomisation only), and induction cohort (maintenance randomisation only). All patients and study site personnel were masked to treatment assignment. Primary endpoints were remission (Mayo Clinic total score [MCS] ≤2, with individual subscores of ≤1 and a rectal bleeding subscore of 0) at week 14, and remission at week 66 among patients with a clinical response (MCS with ≥3-point decrease and ≥30% reduction from baseline, plus ≥1 point decrease in rectal bleeding subscore or absolute rectal bleeding score of 0 or 1) at week 14. Efficacy was analysed using a modified intent-to-treat population. Safety analyses included all patients who received at least one dose of study drug during the induction phase. This study is registered at ClinicalTrials.gov , NCT02100696 . Findings HICKORY was conducted from May 21, 2014, to April 16, 2020, during which time 1081 patients were screened, and 609 deemed eligible for inclusion. 130 patients were included in cohort 1. In cohort 2,479 patients were randomly assigned to the induction phase (etrolizumab n=384, placebo n=95). 232 patients were randomly assigned to the maintenance phase (etrolizumab to etrolizumab n=117, etrolizumab to placebo n=115). At week 14, 71 (18·5%) of 384 patients in the etrolizumab group and six (6·3%) of 95 patients in the placebo group achieved the primary induction endpoint of remission (p=0·0033). No significant difference between etrolizumab and placebo was observed for the primary maintenance endpoint of remission at week 66 among patients with a clinical response at week 14 (27 [24·1%] of 112 vs 23 [20·2%] of 114; p=0·50). Four patients in the etrolizumab group reported treatment-related adverse events leading to treatment discontinuation. The proportion of patients reporting at least adverse event was similar between treatment groups for induction (etrolizumab 253 [66%] of 384; placebo 63 [66%] of 95) and maintenance (etrolizumab to etrolizumab 98 [88%] of 112; etrolizumab to placebo 97 [85%] of 114). The most common adverse event in both groups was ulcerative colitis flare. Most adverse events were mild or moderate. During induction, the most common serious adverse event was ulcerative colitis flare (etrolizumab ten [3%] of 384; placebo: two [2%] of 95). During maintenance, the most common serious adverse event in the etrolizumab to etrolizumab group was appendicitis (two [2%] of 112) and the most common serious adverse events in the etrolizumab to placebo group were ulcerative colitis flare (two [2%] of 114) and anaemia (two [2%] of 114). Interpretation HICKORY demonstrated that a significantly higher proportion of patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agent were able to achieve remission at week 14 when treated with etrolizumab compared with placebo; however, there was no significant difference between groups in remission at week 66 among patients with a clinical response at week 14. Funding F Hoffmann-La Roche.
- Published
- 2022
41. HD2A and HD2C co-regulate drought stress response by modulating stomatal closure and root growth in Arabidopsis.
- Author
-
Tahir MS, Karagiannis J, and Tian L
- Abstract
Histone deacetylase 2 (HD2) is a unique family of histone deacetylases (HDACs) in plants. Despite evidence that certain HD2 family HDACs play an important role in plant growth and stress response, the coordination of HD2s in these processes remains largely unknown. We found that HD2-type, HD2A and HD2C coordinate to play a role in drought stress response in Arabidopsis. We showed that the hd2a . hd2c double mutant (Mac16) exhibit decreased drought survival and increased water loss as compared to the single mutants, hd2a and hd2c . Gene expression analysis showed that the ABI1 and ABI2 genes were upregulated and SLAC1 was downregulated which led to the modified stomatal functioning in the Mac16 as compared to the single mutants. Overexpression of HD2A and HD2C showed enhanced drought survival and decreased water loss. We also showed that the GA2ox1 and GA2ox2 genes, which are involved in the catabolism of bioactive gibberellic acids, were upregulated in the Mac16 as compared to the single mutants, which led to a decreased root growth in the Mac16. Furthermore, we showed that HD2A and HD2C can physically interact and increased genome-wide H3K9 acetylation was observed in the Mac16, compared to the single mutants. Overall, our investigation revealed that HD2A and HD2C coordinate to play a cumulative role in drought stress response and root growth in Arabidopsis., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Tahir, Karagiannis and Tian.)
- Published
- 2022
- Full Text
- View/download PDF
42. Characterization of the Role of SPL9 in Drought Stress Tolerance in Medicago sativa .
- Author
-
Hanly A, Karagiannis J, Lu QSM, Tian L, and Hannoufa A
- Subjects
- Anthocyanins biosynthesis, Anthocyanins genetics, Antioxidants metabolism, Dehydration, Droughts, Gene Expression Regulation, Plant, Medicago sativa genetics, Plant Proteins genetics, Plants, Genetically Modified, RNA Interference, Reactive Oxygen Species metabolism, Medicago sativa physiology, Plant Proteins physiology
- Abstract
Extreme environmental conditions, such as drought, are expected to increase in frequency and severity due to climate change, leading to substantial deficiencies in crop yield and quality. Medicago sativa (alfalfa) is an important crop that is relied upon as a staple source of forage in ruminant feed. Despite its economic importance, alfalfa production is constrained by abiotic stress, including drought. In this report, we investigate the role of Squamosa Promoter Binding Protein-Like 9 ( SPL9 ), a target of miR156, in drought tolerance. Transgenic alfalfa plants with RNAi-silenced MsSPL9 ( SPL9 -RNAi) were compared to wild-type (WT) alfalfa for phenotypic changes and drought tolerance indicators. In SPL9 -RNAi plants, both stem thickness and plant height were reduced in two- and six-month-old alfalfa, respectively; however, yield was unaffected. SPL9 -RNAi plants showed less leaf senescence and had augmented relative water content under drought conditions, indicating that SPL9 -RNAi plants had greater drought tolerance potential than WT plants. Interestingly, SPL9 -RNAi plants accumulated more stress-alleviating anthocyanin compared to WT under both drought and well-watered control conditions, suggesting that MsSPL9 may contribute to drought tolerance in alfalfa, at least in part, by regulating anthocyanin biosynthesis. The results suggest that targeting MsSPL9 is a suitable means for improving alfalfa resilience towards drought conditions.
- Published
- 2020
- Full Text
- View/download PDF
43. The association between increasing levels of O-GlcNAc and galectins in the liver tissue of hibernating thirteen-lined ground squirrels (Ictidomys tridecemlineatus).
- Author
-
Jariwala KA, Sherazi AA, Tazhitdinova R, Shum K, Guevorguian P, Karagiannis J, Staples JF, and Timoshenko AV
- Subjects
- Animals, Glycosylation, Acetylglucosamine metabolism, Galectins metabolism, Hibernation, Liver metabolism, Sciuridae
- Abstract
Post-translational glycosylation of proteins with O-linked β-N-acetylglucosamine (O-GlcNAcylation) and changes of galectin expression profiles are essential in many cellular stress responses. We examine this regulation in the liver tissue of hibernating thirteen-lined ground squirrels (Ictidomys tridecemlineatus) representing a biological model of hypometabolism and physiological stress resistance. The tissue levels of O-GlcNAcylated proteins as well as galectin-1 and galectin-3 proteins detected by immunodot blot assay were significantly lower by 4.6-5.4-, 2.2-2.3- and 2.5-2.9-fold, respectively, in the non-hibernating summer squirrels compared with those in winter, whether hibernating or aroused. However, there were no differences in the expression of genes encoding enzymes involved in O-GlcNAc cycle (O-GlcNAc transferase and O-GlcNAcase) and such galectins as LGALS1, LGALS2, LGALS3, LGALS4 and LGALS9. Only the expression of LGALS8 gene in the liver tissue was significantly decreased by 37.6 ± 0.1% in hibernating ground squirrels relative to summer animals. Considering that the expression of a proven genetic biomarker ELOVL6 encoding ELOVL fatty acid elongase 6 was readily upregulated in non-hibernating animals by 11.3-32.9-fold, marginal differential changes in the expression of galectin genes cannot be classified as biomarkers of hibernation. Thus, this study provides evidence that hibernation in Ictidomys tridecemlineatus is associated with increasing O-GlcNAcylation of liver proteins and suggests that the contribution of galectins deserves further studies at the protein level.
- Published
- 2020
- Full Text
- View/download PDF
44. Effects of Global O -GlcNAcylation on Galectin Gene-expression Profiles in Human Cancer Cell Lines.
- Author
-
Sherazi AA, Jariwala KA, Cybulski AN, Lewis JW, Karagiannis J, Cumming RC, and Timoshenko AV
- Subjects
- Blood Proteins, Enzyme Inhibitors pharmacology, Galectin 3 genetics, Galectin 3 metabolism, Galectins metabolism, Gene Expression Regulation, Neoplastic drug effects, Glycosylation drug effects, HL-60 Cells, HT29 Cells, Humans, MCF-7 Cells, N-Acetylglucosaminyltransferases antagonists & inhibitors, Neoplasms pathology, Transcriptome drug effects, beta-N-Acetylhexosaminidases antagonists & inhibitors, Galectins genetics, N-Acetylglucosaminyltransferases metabolism, Neoplasms genetics, Neoplasms metabolism, beta-N-Acetylhexosaminidases metabolism
- Abstract
Background/aim: The effects of O-linked β-N-acetyl-D-glucosamine (O-GlcNAc) transferase (OGT) and O-GlcNAcase (OGA) inhibitors on galectin gene expression profiles were examined in MCF7, HT-29, and HL-60 cancer cell lines., Materials and Methods: Cell cultures were treated for 24 h with OGA inhibitor thiamet G or OGT inhibitor 2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxy-5-thio-α-D-glucopyranose, and global O-GlcNAc levels and expression of galectin genes were determined using an immunodot blot assay and real-time quantitative polymerase chain reaction., Results: Two galectin genes, LGALS3 in MCF7 cells and LGALS12 in HL-60 cells, were up-regulated by O-GlcNAc, whereas other cell-specific galectins were unresponsive to changes in O-GlcNAc level. Of interest, basal levels of O-GlcNAc in resting HL-60 and HT-29 cells were significantly higher than those in cells differentiated into neutrophilic or enterocytic lineages, respectively., Conclusion: O-GlcNAc-mediated signaling pathways may be involved in regulating the expression of only a limited number of galectin genes. Additional O-GlcNAc-dependent mechanisms may work at the protein level (galectin secretion and intracellular localization) and warrant further investigation., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
45. The Pseudokinase Domain of Saccharomyces cerevisiae Tra1 Is Required for Nuclear Localization and Incorporation into the SAGA and NuA4 Complexes.
- Author
-
Berg MD, Genereaux J, Karagiannis J, and Brandl CJ
- Subjects
- Alleles, Amino Acid Sequence, Genes, Suppressor, Half-Life, Models, Molecular, Phenotype, Phosphatidylinositol 3-Kinases chemistry, Promoter Regions, Genetic genetics, Protein Binding, Protein Domains, Protein Transport, Proteolysis, Saccharomyces cerevisiae growth & development, Saccharomyces cerevisiae metabolism, Stress, Physiological, Synthetic Lethal Mutations, Transcription, Genetic, Cell Nucleus metabolism, Histone Acetyltransferases chemistry, Histone Acetyltransferases metabolism, Multiprotein Complexes metabolism, Saccharomyces cerevisiae Proteins chemistry, Saccharomyces cerevisiae Proteins metabolism, Trans-Activators metabolism
- Abstract
Tra1 is an essential component of the SAGA/SLIK and NuA4 complexes in S. cerevisiae , recruiting these co-activator complexes to specific promoters. As a PIKK family member, Tra1 is characterized by a C-terminal phosphoinositide 3-kinase (PI3K) domain. Unlike other PIKK family members ( e.g. , Tor1, Tor2, Mec1, Tel1), Tra1 has no demonstrable kinase activity. We identified three conserved arginine residues in Tra1 that reside proximal or within the cleft between the N- and C-terminal subdomains of the PI3K domain. To establish a function for Tra1's PI3K domain and specifically the cleft region, we characterized a tra1 allele where these three arginine residues are mutated to glutamine. The half-life of the Tra1[Formula: see text] protein is reduced but its steady state level is maintained at near wild-type levels by a transcriptional feedback mechanism. The tra1 [Formula: see text] allele results in slow growth under stress and alters the expression of genes also regulated by other components of the SAGA complex. Tra1[Formula: see text] is less efficiently transported to the nucleus than the wild-type protein. Likely related to this, Tra1[Formula: see text] associates poorly with SAGA/SLIK and NuA4. The ratio of Spt7
SLIK to Spt7SAGA increases in the tra1 [Formula: see text] strain and truncated forms of Spt20 become apparent upon isolation of SAGA/SLIK. Intragenic suppressor mutations of tra1 [Formula: see text] map to the cleft region further emphasizing its importance. We propose that the PI3K domain of Tra1 is directly or indirectly important for incorporating Tra1 into SAGA and NuA4 and thus the biosynthesis and/or stability of the intact complexes., (Copyright © 2018 Berg et al.)- Published
- 2018
- Full Text
- View/download PDF
46. Using genetic buffering relationships identified in fission yeast to reveal susceptibilities in cells lacking hamartin or tuberin function.
- Author
-
Rayhan A, Faller A, Chevalier R, Mattice A, and Karagiannis J
- Abstract
Tuberous sclerosis complex is an autosomal dominant disorder characterized by benign tumors arising from the abnormal activation of mTOR signaling in cells lacking TSC1 (hamartin) or TSC2 (tuberin) activity. To expand the genetic framework surrounding this group of growth regulators, we utilized the model eukaryote Schizosaccharomyces pombe to uncover and characterize genes that buffer the phenotypic effects of mutations in the orthologous tsc1 or tsc2 loci. Our study identified two genes: fft3 (encoding a DNA helicase) and ypa1 (encoding a peptidyle-prolyl cis/trans isomerase). While the deletion of fft3 or ypa1 has little effect in wild-type fission yeast cells, their loss in tsc1Δ or tsc2Δ backgrounds results in severe growth inhibition. These data suggest that the inhibition of Ypa1p or Fft3p might represent an 'Achilles' heel' of cells defective in hamartin/tuberin function. Furthermore, we demonstrate that the interaction between tsc1 / tsc2 and ypa1 can be rescued through treatment with the mTOR inhibitor, torin-1, and that ypa1Δ cells are resistant to the glycolytic inhibitor, 2-deoxyglucose. This identifies ypa1 as a novel upstream regulator of mTOR and suggests that the effects of ypa1 loss, together with mTOR activation, combine to result in a cellular maladaptation in energy metabolism that is profoundly inhibitory to growth., Competing Interests: Competing interestsThe authors declare no competing or financial interests., (© 2018. Published by The Company of Biologists Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
47. Latrunculin A-Induced Perturbation of the Actin Cytoskeleton Mediates Pap1p-Dependent Induction of the Caf5p Efflux Pump in Schizosaccharomyces pombe .
- Author
-
Asadi F, Chakraborty B, and Karagiannis J
- Subjects
- Actin Cytoskeleton metabolism, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Cell Nucleus drug effects, Cell Nucleus genetics, Cytoplasm drug effects, Cytoplasm genetics, Gene Expression Regulation, Fungal drug effects, Nuclear Export Signals genetics, Oxidative Stress drug effects, Schizosaccharomyces metabolism, Signal Transduction drug effects, Thiazolidines pharmacology, Actin Cytoskeleton genetics, Basic-Leucine Zipper Transcription Factors genetics, Membrane Proteins genetics, Schizosaccharomyces genetics, Schizosaccharomyces pombe Proteins genetics, alpha Karyopherins genetics
- Abstract
As part of an earlier study aimed at uncovering gene products with roles in defending against latrunculin A (LatA)-induced cytoskeletal perturbations, we identified three members of the oxidative stress response pathway: the Pap1p AP-1-like transcription factor, the Imp1p α-importin, and the Caf5p efflux pump. In this report, we characterize the pathway further and show that Pap1p translocates from the cytoplasm to the nucleus in an Imp1p-dependent manner upon LatA treatment. Moreover, preventing this translocation, through the addition of a nuclear export signal (NES), confers the same characteristic LatA-sensitive phenotype exhibited by pap1 Δ cells. Lastly, we show that the caf5 gene is induced upon exposure to LatA and that Pap1p is required for this transcriptional upregulation. Importantly, the expression of trr1 , a Pap1p target specifically induced in response to oxidative stress, is not significantly altered by LatA treatment. Taken together, these results suggest a model in which LatA-mediated cytoskeletal perturbations are sensed, triggering the Imp1p-dependent translocation of Pap1p to the nucleus and the induction of the caf5 gene (independently of oxidative stress)., (Copyright © 2017 Asadi et al.)
- Published
- 2017
- Full Text
- View/download PDF
48. Midkine, a heparin-binding growth factor, and its roles in atherogenesis and inflammatory kidney diseases.
- Author
-
Şalaru DL, Arsenescu-Georgescu C, Chatzikyrkou C, Karagiannis J, Fischer A, and Mertens PR
- Subjects
- Animals, Humans, Midkine, Atherosclerosis physiopathology, Inflammation physiopathology, Kidney Diseases physiopathology, Nerve Growth Factors metabolism
- Abstract
The heparin-binding protein midkine is a potent growth factor with emerging roles in numerous inflammatory diseases. Beyond its characterization in embryogenesis and organ development, ample insights into its function have been collected from experimental disease models using knockout animals or knockdown intervention strategies. Here a comprehensive overview on midkine and its functions in atherogenesis and kidney diseases is provided. Molecular clues to key signalling pathways (Akt, ERK, HIF1α) and key events in atherosclerotic vessels link midkine expression with vascular smooth muscle proliferation and (neo)angiogenesis. In acute and chronic kidney diseases, midkine expression is upregulated in tubular as well as endothelial cells. Experimental disease models that mimic diabetic nephropathy and/or immunologic glomerular damage indicate dichotomous midkine activities, with cytoprotective as well as injurious effects. This review also pinpoints the commonalities of the disease models. An understanding of the underlying molecular events will be required in order to design a targeted intervention into cardiovascular or renal diseases as well as inflammatory processes., (© The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
49. A Genetic Screen for Fission Yeast Gene Deletion Mutants Exhibiting Hypersensitivity to Latrunculin A.
- Author
-
Asadi F, Michalski D, and Karagiannis J
- Subjects
- Cytokinesis drug effects, Cytokinesis genetics, Disk Diffusion Antimicrobial Tests, Dose-Response Relationship, Drug, Gene Expression Regulation, Fungal drug effects, Gene Regulatory Networks drug effects, Microbial Sensitivity Tests, Bridged Bicyclo Compounds, Heterocyclic pharmacology, Marine Toxins pharmacology, Schizosaccharomyces drug effects, Schizosaccharomyces genetics, Schizosaccharomyces pombe Proteins genetics, Sequence Deletion, Thiazolidines pharmacology
- Abstract
Fission yeast cells treated with low doses of the actin depolymerizing drug, latrunculin A (LatA), delay entry into mitosis via a mechanism that is dependent on both the Clp1p and Rad24p proteins. During this delay, cells remain in a cytokinesis-competent state that is characterized by continuous repair and/or reestablishment of the actomyosin ring. In this manner, cells ensure the faithful completion of the preceding cytokinesis in response to perturbation of the cell division machinery. To uncover other genes with a role in this response, or simply genes with roles in adapting to LatA-induced stress, we carried out a genome-wide screen and identified a group of 38 gene deletion mutants that are hyper-sensitive to the drug. As expected, we found genes affecting cytokinesis and/or the actin cytoskeleton within this set (ain1, acp2, imp2). We also identified genes with roles in histone modification (tra1, ngg1), intracellular transport (apl5, aps3), and glucose-mediated signaling (git3, git5, git11, pka1, cgs2). Importantly, while the identified gene deletion mutants are prone to cytokinesis failure in the presence of LatA, they are nevertheless fully capable of cell division in the absence of the drug. These results indicate that fission yeast cells make use of a diverse set of regulatory modules to counter abnormal cytoskeletal perturbations, and furthermore, that these modules act redundantly to ensure cell survival and proliferation., (Copyright © 2016 Asadi et al.)
- Published
- 2016
- Full Text
- View/download PDF
50. Saccharomyces cerevisiae Tti2 Regulates PIKK Proteins and Stress Response.
- Author
-
Hoffman KS, Duennwald ML, Karagiannis J, Genereaux J, McCarton AS, and Brandl CJ
- Subjects
- Alleles, Cell Survival genetics, Gene Expression, HSP90 Heat-Shock Proteins genetics, HSP90 Heat-Shock Proteins metabolism, Molecular Chaperones genetics, Mutation, Protein Transport, Saccharomyces cerevisiae growth & development, Saccharomyces cerevisiae Proteins genetics, Signal Transduction, Molecular Chaperones metabolism, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae metabolism, Saccharomyces cerevisiae Proteins metabolism, Stress, Physiological genetics
- Abstract
The TTT complex is composed of the three essential proteins Tel2, Tti1, and Tti2 The complex is required to maintain steady state levels of phosphatidylinositol 3-kinase-related kinase (PIKK) proteins, including mTOR, ATM/Tel1, ATR/Mec1, and TRRAP/Tra1, all of which serve as regulators of critical cell signaling pathways. Due to their association with heat shock proteins, and with newly synthesized PIKK peptides, components of the TTT complex may act as cochaperones. Here, we analyze the consequences of depleting the cellular level of Tti2 in Saccharomyces cerevisiae We show that yeast expressing low levels of Tti2 are viable under optimal growth conditions, but the cells are sensitive to a number of stress conditions that involve PIKK pathways. In agreement with this, depleting Tti2 levels decreased expression of Tra1, Mec1, and Tor1, affected their localization and inhibited the stress responses in which these molecules are involved. Tti2 expression was not increased during heat shock, implying that it does not play a general role in the heat shock response. However, steady state levels of Hsp42 increase when Tti2 is depleted, and tti2L187P has a synthetic interaction with exon 1 of the human Huntingtin gene containing a 103 residue polyQ sequence, suggesting a general role in protein quality control. We also find that overexpressing Hsp90 or its cochaperones is synthetic lethal when Tti2 is depleted, an effect possibly due to imbalanced stoichiometry of a complex required for PIKK assembly. These results indicate that Tti2 does not act as a general chaperone, but may have a specialized function in PIKK folding and/or complex assembly., (Copyright © 2016 Hoffman et al.)
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.